Trial · NCT00261846
Participant flow72
How many started, completed or left each group, period by period.
1 to 20 of 72
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Period 1: Part 1 (Dose Escalation) | STARTED | Bosutinib 400 mg (Part 1) | 3 | |
| Period 1: Part 1 (Dose Escalation) | STARTED | Bosutinib 500 mg (Part 1) | 3 | |
| Period 1: Part 1 (Dose Escalation) | STARTED | Bosutinib 600 mg (Part 1) | 12 | |
| Period 1: Part 1 (Dose Escalation) | STARTED | Bosutinib 500 mg, CP2L-CML IM-R (Part 2) | 0 | |
| Period 1: Part 1 (Dose Escalation) | STARTED | Bosutinib 500 mg, CP2L-CML IM-I (Part 2) | 0 | |
| Period 1: Part 1 (Dose Escalation) | STARTED | Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2) | 0 | |
| Period 1: Part 1 (Dose Escalation) | STARTED | Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2) | 0 | |
| Period 1: Part 1 (Dose Escalation) | STARTED | Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2) | 0 | |
| Period 1: Part 1 (Dose Escalation) | STARTED | Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2) | 0 | |
| Period 1: Part 1 (Dose Escalation) | STARTED | AP-CML Total (Part 2) | 0 | |
| Period 1: Part 1 (Dose Escalation) | STARTED | BP-CML Total (Part 2) | 0 | |
| Period 1: Part 1 (Dose Escalation) | STARTED | Bosutinib 500 mg, Ph+ ALL (Part 2) | 0 | |
| Period 1: Part 1 (Dose Escalation) | COMPLETED | Bosutinib 400 mg (Part 1) | 0 | |
| Period 1: Part 1 (Dose Escalation) | COMPLETED | Bosutinib 500 mg (Part 1) | 0 | |
| Period 1: Part 1 (Dose Escalation) | COMPLETED | Bosutinib 600 mg (Part 1) | 0 | |
| Period 1: Part 1 (Dose Escalation) | COMPLETED | Bosutinib 500 mg, CP2L-CML IM-R (Part 2) | 0 | |
| Period 1: Part 1 (Dose Escalation) | COMPLETED | Bosutinib 500 mg, CP2L-CML IM-I (Part 2) | 0 | |
| Period 1: Part 1 (Dose Escalation) | COMPLETED | Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2) | 0 | |
| Period 1: Part 1 (Dose Escalation) | COMPLETED | Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2) | 0 | |
| Period 1: Part 1 (Dose Escalation) | COMPLETED | Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00261846/flow